Profile data is unavailable for this security.
About the company
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
- Revenue in USD (TTM)15.73m
- Net income in USD-72.73m
- Incorporated2002
- Employees104.00
- LocationDbv Technologies SA177-181 avenue Pierre BrossoletteMONTROUGE 92120FranceFRA
- Phone+33 155427878
- Fax+33 143261083
- Websitehttps://www.dbv-technologies.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | 176.23m | -257.83m | 115.33m | 405.00 | -- | 1.19 | -- | 0.6544 | -1.46 | -1.46 | 1.01 | 0.4653 | 0.4843 | -- | 76.61 | 435,140.80 | -70.85 | -26.09 | -90.72 | -31.04 | -- | -- | -146.30 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Hongchang International Co Ltd | 2.68m | -378.79k | 115.49m | 8.00 | -- | 2.85 | -- | 43.16 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -36.90m | 117.94m | 35.00 | -- | 3.07 | -- | 11,794.42 | -0.5841 | -0.5841 | 0.0002 | 0.5966 | 0.0002 | -- | 0.0625 | 285.71 | -75.98 | -43.60 | -90.65 | -47.82 | -- | -- | -368,994.20 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 119.15m | 143.00 | -- | 0.3687 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 121.61m | 37.00 | -- | 0.9864 | -- | 116.68 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 122.05m | 54.00 | -- | 1.36 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 122.79m | 168.00 | -- | 0.8108 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Immunic Inc | 0.00 | -93.61m | 123.41m | 77.00 | -- | 2.14 | -- | -- | -2.11 | -2.11 | 0.00 | 0.6404 | 0.00 | -- | -- | 0.00 | -102.84 | -72.09 | -129.79 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| DBV Technologies SA - ADR | 15.73m | -72.73m | 123.70m | 104.00 | -- | 0.9154 | -- | 7.86 | -0.3832 | -0.3832 | 0.0827 | 0.7286 | 0.0732 | -- | 1.18 | 151,240.40 | -33.87 | -- | -40.11 | -- | -- | -- | -462.37 | -- | -- | -- | 0.00 | -- | 224.69 | -- | 24.46 | -- | -- | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 125.83m | 84.00 | -- | 8.23 | -- | 35.95 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Vaxart Inc | 7.38m | -82.47m | 126.73m | 109.00 | -- | 1.93 | -- | 17.17 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 126.75m | 8.00 | -- | 3.51 | -- | 21.12 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 127.18m | 22.00 | -- | 1.32 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| FitLife Brands Inc | 52.70m | 5.30m | 128.52m | 37.00 | 25.85 | 4.75 | 23.84 | 2.44 | 1.08 | 1.08 | 10.74 | 5.88 | 1.30 | 3.44 | 38.31 | 1,424,297.00 | 13.07 | 26.40 | 15.94 | 33.92 | 40.67 | 42.09 | 10.05 | 17.65 | 0.5419 | 16.81 | 0.4253 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Biostem Technologies Inc | 16.69m | -7.86m | 129.72m | 67.00 | -- | -- | -- | 7.77 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
| Karyopharm Therapeutics Inc | 146.03m | -143.10m | 131.61m | 325.00 | -- | -- | -- | 0.9012 | -1.25 | -1.25 | 1.28 | -1.19 | 0.4879 | 1.36 | 3.94 | 449,332.30 | -47.81 | -53.02 | -61.78 | -65.85 | 96.62 | 97.18 | -97.99 | -125.15 | 3.32 | -10.06 | 1.81 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to Dbv Technologies SA's reporting currency: US Dollar USD
17.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2023 | 14.61m | 7.58% |
| Braidwell LPas of 31 Dec 2023 | 7.84m | 4.07% |
| Yiheng Capital Management LPas of 31 Dec 2023 | 5.24m | 2.72% |
| Point72 Asset Management LPas of 31 Dec 2023 | 3.11m | 1.61% |
| Millennium Management LLCas of 31 Dec 2023 | 630.97k | 0.33% |
| Morgan Stanley & Co. International Plcas of 31 Dec 2023 | 628.18k | 0.33% |
| Threadneedle Asset Management Ltd.as of 31 Dec 2023 | 574.36k | 0.30% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 538.71k | 0.28% |
| Citadel Securities LLCas of 31 Dec 2023 | 163.35k | 0.09% |
| HRT Financial LLCas of 31 Dec 2023 | 151.99k | 0.08% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
